Khalafallah, A A <br/><br/>
Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study.  [electronic resource] 

 -  European journal of cancer care  Mar 2018 
 - e12638 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase IV; Journal Article; Multicenter Study; Observational Study 
<br/><br/><label>ISSN: </label>1365-2354 
<br/><br/><label>Standard No.: </label>10.1111/ecc.12638  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Bone Density Conservation Agents--adverse effects<br/>Bone Diseases--drug therapy<br/>Diphosphonates--adverse effects<br/>Female<br/>Humans<br/>Imidazoles--adverse effects<br/>Kaplan-Meier Estimate<br/>Longitudinal Studies<br/>Male<br/>Middle Aged<br/>Neoplasms--complications<br/>Prospective Studies<br/>Zoledronic Acid